尿毒症患者血浆TFPI与AT-Ⅲ的检测及临床意义  

Measurement of Tissue Factor Pathway Inhibitor and Antithrombin-Ⅲ and its Clinical Significance in Patients with Uremia

作　　者：刘敏涓[1] 周立红[1] 刘泽霖[1] 谭获[1] 赖毅妍[1] 

机构地区：[1]广州医学院第二附属医院

出　　处：《广州医药》1999年第1期13-15,共3页Guangzhou Medical Journal

摘　　要：目的：对尿毒症患者的血浆中抗凝物质－组织因子途径抑制物（ＴＦＰＩ）与抗凝血酶Ⅲ（ＡＴ－Ⅲ）进行测定以研究其病理改变与凝血机理的关系，以及透析治疗对它的影响。方法：ＴＦＰＩ抗原（ＴＦＰＩ：Ａｇ）测定采用酶联免疫（ＥＬＩＳＡ）方法，ＡＴ－Ⅲ活性（ＡＴ－Ⅲ：Ａ）测定采用发色底物法。结果：尿毒症组（２０例）ＴＦＰＩ：Ａｇ为１７７３５±４６５８ｎｇ／ｍｌ，较正常组（３０例）为高（Ｐ＜００１）；ＡＴ－Ⅲ：Ａ为７３１１０±１７０１，较正常组为低（Ｐ＜００１）。尿毒症组（１０例）透析前后比较：ＴＦＰＩ：Ａｇ从１８２９１±３１２０降至１３１５５±３６５１（Ｐ＜００１）；ＡＴ－Ⅲ：Ａ从８４２６±１６１９升至１１０００±２６５１（Ｐ＜００１）。结论：尿毒症患者ＴＦＰＩ：Ａｇ增高，ＡＴ－Ⅲ：Ａ降低，表明其组织病理损伤明显而致ＴＦ过度表达，从而呈现一定程度的高凝状态。透析治疗可使此病理过程得到一定程度的矫正。Objective: To observe measurement of coagulation Inhibitors-Tissue Factor Pathway Inhibitor (TFPI) and Antithrombin-Ⅲ(AT-Ⅲ)in Patients with Uremia To study the relationship between pathologic change and coagulation mechanism, and its effected by hemodialysis Methods: TFPI Antigen (TFPI:Ag) was determined with an enzyme-linked immunity (ELISA) AT-Ⅲ active (AT-Ⅲ:A) was determined with chromogenic peptide substrate Results: uremia groups (20 cases) plasma levels of TFPI:Ag were 177 35± 46 58 ng/ml, higher than the healthy subjects (30 cases) ( P <0 01); AT-Ⅲ:A were 73 10±17 01, lower than controls ( P <0 01) The 10 cases of uremia compared before hemodialys and after hemodialysis TFPI:Ag from 182 91±31 20 decreases to 131 55± 36 51 ( P <0 005); AT-Ⅲ:A from 84 26±16 19 elevated to 110 00±26 51 ( P <0 01) Conclusion: uremic patients TFPI:Ag increases and AT-Ⅲ:A decreases point to severe lesion on kidney tissue arise from tissue factor obvious elevated; the patients prome to hyper coagulable state and this state were changed to normal levels by hemodialysis

关 键 词：尿毒症 TFPI 抗凝血酶Ⅲ 血浆 测定 

分 类 号：R695[医药卫生—泌尿科学]